查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477979

結核分枝桿菌治療市場：依產品類型、最終用戶、地區 - 全球產業分析、規模、佔有率、成長、趨勢、預測，2024-2032 年

Mycobacterium Tuberculosis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
出版日期: | 出版商: Persistence Market Research | 英文 287 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

Persistence Market Research 的結核分枝桿菌治療市場研究報告詳細分析了 2024 年至 2032 年的市場趨勢、成長動力和課題以及未來的技術創新。提供對市場當前狀況和未來預測的洞察。

全球結核分枝桿菌藥物市場預計將從2024年的21.3億美元成長到2032年的24億美元，複合年增長率為1.2%。

重要見解

  • 預計市場規模（2024年）：21.3億美元
  • 預測市場規模（2032年）：24億美元
  • 全球市場成長率（2024-2032年複合年增長率）：1.2%

結核分枝桿菌治療市場 - 報告範圍：

結核分枝桿菌是一種引起結核病的細菌，它主要影響肺部，但也可以侵入其他器官。本報告強調了推動結核分枝桿菌治療需求的因素，包括全球結核病病例數量的增加、結核病研究資金的增加以及診斷技術的改進。

市場驅動因素：

由於多種因素，對結核分枝桿菌治療的需求正在增加。這一增長是由全球結核病患者數量的增加、篩檢和診斷工具的改進以及更快速和有效的藥物治療方案的開發所推動的。抗藥性結核病的增加正在刺激對新治療方法的研究，包括合併治療和長期疫苗策略。此外，全球健康倡議和結核病計畫資助正在顯著促進市場擴張。

市場限制：

結核分枝桿菌治療市場面臨課題，例如先進的結核分枝桿菌藥物成本高、低收入國家獲得醫療設施的機會有限以及治療不遵從率高。治療抗藥性結核病的複雜性和治療時間的長短也阻礙了市場的成長。監管的複雜性和針對特定國家的政府政策可能會延遲新療法的推出。

市場機會：

結核分枝桿菌治療市場有重大創新機會。分子生物學和基因工程的進步提供了開發更有效對抗抗藥性結核菌株的新療法的潛力。公私夥伴關係和國際合作可以加速研究和開發工作，而加強公共衛生運動可以提高意識、改善早期發現和遵守治療方案。

本報告解決的關鍵問題

  • 2024年至2032年結核分枝桿菌治療市場的預期複合年增長率為何？
  • 推動結核分枝桿菌治療市場成長的關鍵因素是什麼？
  • 哪種治療方式擁有最大的市場佔有率？
  • 誰是全球結核分枝桿菌治療市場的主要參與者？
  • 領先企業採取哪些策略來保持競爭力？

目錄

第一章執行摘要

第二章市場概況

  • 市場範圍/分類
  • 市場定義/範圍/限制
  • 包容與排除

第 3 章主要市場趨勢

  • 影響市場的主要趨勢
  • 產品創新/發展趨勢

第 4 章關鍵成功因素

  • 依地區劃分的疾病流行病學
  • 監管場景
  • PESTLE分析
  • 波特的分析
  • 廠商主要促銷策略
  • 供應鏈分析

第五章市場背景

  • 宏觀經濟因素
  • 預測變量 - 相關性和影響
  • 市場動態

第 6 章 COVID-19 危機分析

  • COVID-19 與影響分析
    • 依疾病劃分的收入
    • 依治療類型劃分的收入
    • 依管理途徑劃分的收入
    • 依分銷管道劃分的收入
    • 依國家/地區劃分的收入
  • 2024年市場情景

第七章全球結核分枝桿菌治療市場需求分析

  • 過往市值分析（2019-2023）
  • 目前和未來的市值預測（2024-2032）
    • 同比增長趨勢分析
    • 絕對量機會分析

第八章全球結核分枝桿菌治療市場分析：依疾病分類

  • 簡介/主要發現
  • 過去的市場規模分析：依疾病分類（2019-2023）
  • 目前和未來的市場規模分析和預測：依疾病分類（2024-2032）
    • 潛伏性結核病
    • 活動性結核病
  • 依疾病劃分的市場吸引力分析

第九章全球結核分枝桿菌治療市場分析：依治療類型

  • 簡介/主要發現
  • 歷史市場規模分析：依治療類型（2019-2023）
  • 目前和未來的市場規模分析和預測：依治療類型（2024-2032）
    • 首選藥物
    • 第二選擇藥物
  • 依治療類型分析市場吸引力

第10章全球結核分枝桿菌治療市場分析：依給藥途徑

  • 簡介/主要發現
  • 過去的市場規模分析：依管理途徑（2019-2023）
  • 目前和未來的市場規模分析和預測：依管理方式（2024-2032）
    • 口服
    • 靜脈
    • 肌肉內
  • 依給藥途徑進行的市場吸引力分析

第十一章全球結核分枝桿菌治療市場分析：依通路

  • 簡介/主要發現
  • 過去的市場規模分析：依分銷管道劃分（2019-2023）
  • 目前和未來的市場規模分析和預測：依分銷管道劃分（2024-2032）
    • 醫院藥房
    • 網上藥店
    • 零售藥店
    • 企業及個人銷售
  • 依分銷管道劃分的市場吸引力分析

第十二章全球結核分枝桿菌治療市場分析：依地區

  • 介紹
  • 過去的市場規模分析：依地區（2019-2023）
  • 目前和未來的市場規模分析和預測：依地區（2024-2032）
    • 北美
    • 拉丁美洲
    • 歐洲
    • 東亞
    • 南亞
    • 大洋洲
    • 中東/非洲
  • 依地區劃分的市場吸引力分析

第十三章北美結核病治療市場分析

第十四章拉丁美洲結核分枝桿菌治療市場分析

第十五章歐洲結核分枝桿菌治療市場分析

第十六章南亞結核菌治療市場分析

第十七章東亞結核病治療市場分析

第十八章 大洋洲結核分枝桿菌治療市場分析

第十九章中東與非洲結核分枝桿菌治療市場分析

第二十章市場結構分析

  • 依公司層級進行市場分析
  • 主要參與者的市場佔有率分析
  • 市場存在分析

第 21 章 競爭分析

  • 比賽儀表板
  • 競爭標桿
  • 衝突詳情
    • AstraZeneca
    • Johnson & Johnson Private Limited
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma
    • Lupin
    • Allergan
    • Merck & Co., Inc.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Hikma Pharmaceuticals PLC
    • Cipla Inc.
    • Endo International plc
    • Otsuka Pharmaceutical Co., Ltd.
    • STI Pharma, LLC

第22章假設和縮寫

第23章研究方法論

簡介目錄
Product Code: PMRREP33190

The Mycobacterium Tuberculosis Treatment Market report by Persistence Market Research provides an in-depth analysis of the market trends, growth drivers, challenges, and prospective innovations spanning from 2024 to 2032. It offers insights into the current landscape and future projections of the market.

The global market for Mycobacterium tuberculosis treatment is expected to achieve a compound annual growth rate (CAGR) of 1.2% from USD 2.13 billion in 2024 to USD 2.40 billion by 2032.

Key Insights:

  • Estimated Market Size (2024): USD 2.13 Billion
  • Projected Market Size (2032): USD 2.40 Billion
  • Global Market Growth Rate (CAGR 2024 to 2032): 1.2%

Mycobacterium Tuberculosis Treatment Market - Report Scope:

Mycobacterium tuberculosis is the bacterium that causes tuberculosis (TB), primarily affecting the lungs but can invade other organs. This report focuses on the drivers promoting the demand for TB treatment, including the global rise in TB cases, increased funding for TB research, and enhancements in diagnostic technologies.

Market Growth Drivers:

The demand for TB treatment is escalating due to several factors. The increase in TB cases globally, enhanced screening and diagnostic measures, and the development of faster-acting and more effective drug regimens drive this growth. The rise of drug-resistant TB forms has spurred research into novel treatment approaches, including combination therapies and longer-term vaccine strategies. Additionally, global health initiatives and funding for TB programs significantly propel market expansion.

Market Restraints:

The Mycobacterium Tuberculosis Treatment Market faces challenges such as the high cost of advanced TB drugs, limited access to medical facilities in low-income countries, and significant rates of treatment non-compliance. The complexity of managing drug-resistant TB and the long duration of treatment also hinder market growth. Regulatory complexities and varying government policies across countries can delay the introduction of new treatments.

Market Opportunities:

Significant opportunities exist for innovation within the TB treatment market. Advances in molecular biology and genetic engineering offer potential for developing new treatments that are more effective against drug-resistant strains of TB. Public-private partnerships and international collaborations can accelerate research and development efforts, while increasing public health campaigns can raise awareness and improve early detection and compliance with treatment protocols.

Key Questions Addressed in the Report:

  • What is the Expected CAGR of the Mycobacterium Tuberculosis Treatment Market from 2024 to 2032?
  • What are the Key Factors Driving the Growth of the Mycobacterium Tuberculosis Treatment Market?
  • Which Treatment Modality Holds the Largest Market Share?
  • Who are the Key Players in the Global Mycobacterium Tuberculosis Treatment Market?
  • What Strategies are Adopted by Leading Companies to Remain Competitive?

Competitive Landscape and Business Strategies:

Key players in the market include Johnson & Johnson, Sanofi, Bayer AG, and GlaxoSmithKline plc. These companies focus on innovations in TB treatment, market penetration in untapped regions, and forming strategic partnerships to stay competitive. For instance, Johnson & Johnson offers Sirturo for multi-drug resistant TB, and Sanofi has been involved in developing booster combinations to enhance treatment efficacy.

Key Companies Profiled:

  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Allergan
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.
  • Endo International plc
  • Otsuka Pharmaceutical Co., Ltd.
  • STI Pharma, LLC

Mycobacterium Tuberculosis Treatment Market Segmentation:

By Disease Type:

  • Latent TB
  • Active TB

By Treatment Type:

  • First-Line of Drugs
  • Second-Line of Drugs

By Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Institutional and Retail Sales

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply-Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Disease Epidemiology, By Region
  • 4.2. Regulatory Scenario
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Analysis
  • 4.5. Key Promotional Strategies, by Manufacturers
  • 4.6. Supply Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure
    • 5.1.3. Global Infectious Disease Treatment Market
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Growing Burden of Tuberculosis Disease
    • 5.2.2. Increasing Research and Development Activities
    • 5.2.3. Adoption of Different Treatments for Infectious Disease
    • 5.2.4. Rising Government Support
    • 5.2.5. Increasing FDA Approvals of New Drugs
    • 5.2.6. Strategic Mergers and Acquisitions Among Local Manufacturers
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. Revenue By Disease Type
    • 6.1.2. Revenue By Treatment Type
    • 6.1.3. Revenue By Route of Administration
    • 6.1.4. Revenue By Distribution Channel
    • 6.1.5. Revenue By Country
  • 6.2. 2024 Market Scenario

7. Global Mycobacterium Tuberculosis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Disease Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2024-2032
    • 8.3.1. Latent TB
    • 8.3.2. Active TB
  • 8.4. Market Attractiveness Analysis By Disease Type

9. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Treatment Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2024-2032
    • 9.3.1. First-Line of Drugs
    • 9.3.2. Second-Line of Drugs
  • 9.4. Market Attractiveness Analysis By Treatment Type

10. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2032
    • 10.3.1. Oral
    • 10.3.2. Intravenous
    • 10.3.3. Intramuscular
  • 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2032
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Online Pharmacies
    • 11.3.3. Retail Pharmacies
    • 11.3.4. Institutional and Retail Sales
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Disease Type
    • 13.3.3. By Treatment Type
    • 13.3.4. By Route of Administration
    • 13.3.5. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Disease Type
    • 13.4.3. By Treatment Type
    • 13.4.4. By Route of Administration
    • 13.4.5. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Mycobacterium Tuberculosis Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Disease Type
        • 13.8.1.2.2. By Treatment Type
        • 13.8.1.2.3. By Route of Administration
        • 13.8.1.2.4. By Distribution Channel
    • 13.8.2. Canada Mycobacterium Tuberculosis Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Disease Type
        • 13.8.2.2.2. By Treatment Type
        • 13.8.2.2.3. By Route of Administration
        • 13.8.2.2.4. By Distribution Channel

14. Latin America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Rest of Latin America
    • 14.3.2. By Disease Type
    • 14.3.3. By Treatment Type
    • 14.3.4. By Route of Administration
    • 14.3.5. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Disease Type
    • 14.4.3. By Treatment Type
    • 14.4.4. By Route of Administration
    • 14.4.5. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Disease Type
        • 14.8.1.2.2. By Treatment Type
        • 14.8.1.2.3. By Route of Administration
        • 14.8.1.2.4. By Distribution Channel
    • 14.8.2. Argentina Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Disease Type
        • 14.8.2.2.2. By Treatment Type
        • 14.8.2.2.3. By Route of Administration
        • 14.8.2.2.4. Distribution Channel
    • 14.8.3. Mexico Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Disease Type
        • 14.8.3.2.2. By Treatment Type
        • 14.8.3.2.3. By Route of Administration
        • 14.8.3.2.4. By Distribution Channel

15. Europe Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Nordic Countries
      • 15.3.1.8. Russia
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By Disease Type
    • 15.3.3. By Treatment Type
    • 15.3.4. By Route of Administration
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Disease Type
    • 15.4.3. By Treatment Type
    • 15.4.4. By Route of Administration
    • 15.4.5. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Disease Type
        • 15.8.1.2.2. By Treatment Type
        • 15.8.1.2.3. By Route of Administration
        • 15.8.1.2.4. By Distribution Channel
    • 15.8.2. France Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Disease Type
        • 15.8.2.2.2. By Treatment Type
        • 15.8.2.2.3. By Route of Administration
        • 15.8.2.2.4. By Distribution Channel
    • 15.8.3. Italy Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Disease Type
        • 15.8.3.2.2. By Treatment Type
        • 15.8.3.2.3. By Route of Administration
        • 15.8.3.2.4. By Distribution Channel
    • 15.8.4. Spain Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Disease Type
        • 15.8.4.2.2. By Treatment Type
        • 15.8.4.2.3. By Route of Administration
        • 15.8.4.2.4. By Distribution Channel
    • 15.8.5. U.K. Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Disease Type
        • 15.8.5.2.2. By Treatment Type
        • 15.8.5.2.3. By Route of Administration
        • 15.8.5.2.4. By Distribution Channel
    • 15.8.6. Benelux Union Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Disease Type
        • 15.8.6.2.2. By Treatment Type
        • 15.8.6.2.3. By Route of Administration
        • 15.8.6.2.4. By Distribution Channel
    • 15.8.7. Nordic Countries Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Disease Type
        • 15.8.7.2.2. By Treatment Type
        • 15.8.7.2.3. By Route of Administration
        • 15.8.7.2.4. By Distribution Channel
    • 15.8.8. Russia Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.8.1. Introduction
      • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.8.2.1. By Disease Type
        • 15.8.8.2.2. By Treatment Type
        • 15.8.8.2.3. By Route of Administration
        • 15.8.8.2.4. By Distribution Channel

16. South Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Indonesia
      • 16.3.1.4. Malaysia
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Disease Type
    • 16.3.3. By Treatment Type
    • 16.3.4. By Route of Administration
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Disease Type
    • 16.4.3. By Treatment Type
    • 16.4.4. By Route of Administration
    • 16.4.5. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Disease Type
        • 16.8.1.2.2. By Treatment Type
        • 16.8.1.2.3. By Route of Administration
        • 16.8.1.2.4. By Distribution Channel
    • 16.8.2. Indonesia Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Disease Type
        • 16.8.2.2.2. By Treatment Type
        • 16.8.2.2.3. By Route of Administration
        • 16.8.2.2.4. By Distribution Channel
    • 16.8.3. Malaysia Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Disease Type
        • 16.8.3.2.2. By Treatment Type
        • 16.8.3.2.3. By Route of Administration
        • 16.8.3.2.4. By Distribution Channel
        • 16.8.3.2.5. By Distribution Channel
    • 16.8.4. Thailand Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Disease Type
        • 16.8.4.2.2. By Treatment Type
        • 16.8.4.2.3. By Route of Administration
        • 16.8.4.2.4. By Distribution Channel

17. East Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Disease Type
    • 17.3.3. By Treatment Type
    • 17.3.4. By Route of Administration
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Disease Type
    • 17.4.3. By Treatment Type
    • 17.4.4. By Route of Administration
    • 17.4.5. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Disease Type
        • 17.8.1.2.2. By Treatment Type
        • 17.8.1.2.3. By Route of Administration
        • 17.8.1.2.4. By Distribution Channel
    • 17.8.2. Japan Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Disease Type
        • 17.8.2.2.2. By Treatment Type
        • 17.8.2.2.3. By Route of Administration
        • 17.8.2.2.4. By Distribution Channel
    • 17.8.3. South Korea Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Disease Type
        • 17.8.3.2.2. By Treatment Type
        • 17.8.3.2.3. By Route of Administration
        • 17.8.3.2.4. By Distribution Channel

18. Oceania Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Disease Type
    • 18.3.3. By Treatment Type
    • 18.3.4. By Route of Administration
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Disease Type
    • 18.4.3. By Treatment Type
    • 18.4.4. By Route of Administration
    • 18.4.5. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Mycobacterium Tuberculosis Treatment Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Disease Type
        • 18.8.1.2.2. By Treatment Type
        • 18.8.1.2.3. By Route of Administration
        • 18.8.1.2.4. By Distribution Channel
    • 18.8.2. New Zealand Mycobacterium Tuberculosis Treatment Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Disease Type
        • 18.8.2.2.2. By Treatment Type
        • 18.8.2.2.3. By Route of Administration
        • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. North Africa
      • 19.3.1.4. South Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Disease Type
    • 19.3.3. By Treatment Type
    • 19.3.4. By Route of Administration
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Disease Type
    • 19.4.3. By Treatment Type
    • 19.4.4. By Route of Administration
    • 19.4.5. By Distribution Channel
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Disease Type
        • 19.8.1.2.2. By Treatment Type
        • 19.8.1.2.3. By Route of Administration
        • 19.8.1.2.4. By Distribution Channel
    • 19.8.2. Turkey Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Disease Type
        • 19.8.2.2.2. By Treatment Type
        • 19.8.2.2.3. By Route of Administration
        • 19.8.2.2.4. By Distribution Channel
    • 19.8.3. North Africa Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Disease Type
        • 19.8.3.2.2. By Treatment Type
        • 19.8.3.2.3. By Route of Administration
        • 19.8.3.2.4. By Distribution Channel
    • 19.8.4. South Africa Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Disease Type
        • 19.8.4.2.2. By Treatment Type
        • 19.8.4.2.3. By Route of Administration
        • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional Footprint Analysis
    • 20.3.2. Channel Footprint Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. AstraZeneca
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Key Financials
      • 21.3.1.4. SWOT Analysis
      • 21.3.1.5. Sales Footprint
      • 21.3.1.6. Strategy Overview
      • 21.3.1.7. Key Developments
        • 21.3.1.7.1. Marketing Strategies
        • 21.3.1.7.2. Channel Strategies
    • 21.3.2. Johnson & Johnson Private Limited
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Key Financials
      • 21.3.2.4. SWOT Analysis
      • 21.3.2.5. Sales Footprint
      • 21.3.2.6. Strategy Overview
      • 21.3.2.7. Key Developments
        • 21.3.2.7.1. Marketing Strategies
        • 21.3.2.7.2. Channel Strategies
    • 21.3.3. Eli Lilly and Company
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Key Financials
      • 21.3.3.4. SWOT Analysis
      • 21.3.3.5. Sales Footprint
      • 21.3.3.6. Strategy Overview
      • 21.3.3.7. Key Developments
        • 21.3.3.7.1. Marketing Strategies
        • 21.3.3.7.2. Channel Strategies
    • 21.3.4. F. Hoffmann-La Roche Ltd.
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Key Financials
      • 21.3.4.4. SWOT Analysis
      • 21.3.4.5. Sales Footprint
      • 21.3.4.6. Strategy Overview
      • 21.3.4.7. Key Developments
        • 21.3.4.7.1. Marketing Strategies
        • 21.3.4.7.2. Channel Strategies
    • 21.3.5. Mylan N.V.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Key Financials
      • 21.3.5.4. SWOT Analysis
      • 21.3.5.5. Sales Footprint
      • 21.3.5.6. Strategy Overview
      • 21.3.5.7. Key Developments
        • 21.3.5.7.1. Marketing Strategies
        • 21.3.5.7.2. Channel Strategies
    • 21.3.6. Teva Pharmaceutical Industries Ltd.
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Key Financials
      • 21.3.6.4. SWOT Analysis
      • 21.3.6.5. Sales Footprint
      • 21.3.6.6. Strategy Overview
      • 21.3.6.7. Key Developments
        • 21.3.6.7.1. Marketing Strategies
        • 21.3.6.7.2. Channel Strategies
    • 21.3.7. Sanofi
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Key Financials
      • 21.3.7.4. SWOT Analysis
      • 21.3.7.5. Sales Footprint
      • 21.3.7.6. Strategy Overview
      • 21.3.7.7. Key Developments
        • 21.3.7.7.1. Marketing Strategies
        • 21.3.7.7.2. Channel Strategies
    • 21.3.8. Novartis AG
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Key Financials
      • 21.3.8.4. SWOT Analysis
      • 21.3.8.5. Sales Footprint
      • 21.3.8.6. Strategy Overview
      • 21.3.8.7. Key Developments
        • 21.3.8.7.1. Marketing Strategies
        • 21.3.8.7.2. Channel Strategies
    • 21.3.9. Sun Pharmaceutical Industries Ltd.
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Key Financials
      • 21.3.9.4. SWOT Analysis
      • 21.3.9.5. Sales Footprint
      • 21.3.9.6. Strategy Overview
      • 21.3.9.7. Key Developments
        • 21.3.9.7.1. Marketing Strategies
        • 21.3.9.7.2. Channel Strategies
    • 21.3.10. Aurobindo Pharma
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Key Financials
      • 21.3.10.4. SWOT Analysis
      • 21.3.10.5. Sales Footprint
      • 21.3.10.6. Strategy Overview
      • 21.3.10.7. Key Developments
        • 21.3.10.7.1. Marketing Strategies
        • 21.3.10.7.2. Channel Strategies
    • 21.3.11. Lupin
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Key Financials
      • 21.3.11.4. SWOT Analysis
      • 21.3.11.5. Sales Footprint
      • 21.3.11.6. Strategy Overview
      • 21.3.11.7. Key Developments
        • 21.3.11.7.1. Marketing Strategies
        • 21.3.11.7.2. Channel Strategies
    • 21.3.12. Allergan
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Key Financials
      • 21.3.12.4. SWOT Analysis
      • 21.3.12.5. Sales Footprint
      • 21.3.12.6. Strategy Overview
      • 21.3.12.7. Key Developments
        • 21.3.12.7.1. Marketing Strategies
        • 21.3.12.7.2. Channel Strategies
    • 21.3.13. Merck & Co., Inc.
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Key Financials
      • 21.3.13.4. SWOT Analysis
      • 21.3.13.5. Sales Footprint
      • 21.3.13.6. Strategy Overview
      • 21.3.13.7. Key Developments
        • 21.3.13.7.1. Marketing Strategies
        • 21.3.13.7.2. Channel Strategies
    • 21.3.14. Pfizer Inc.
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Key Financials
      • 21.3.14.4. SWOT Analysis
      • 21.3.14.5. Sales Footprint
      • 21.3.14.6. Strategy Overview
      • 21.3.14.7. Key Developments
        • 21.3.14.7.1. Marketing Strategies
        • 21.3.14.7.2. Channel Strategies
    • 21.3.15. GlaxoSmithKline plc
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Key Financials
      • 21.3.15.4. SWOT Analysis
      • 21.3.15.5. Sales Footprint
      • 21.3.15.6. Strategy Overview
      • 21.3.15.7. Key Developments
        • 21.3.15.7.1. Marketing Strategies
        • 21.3.15.7.2. Channel Strategies
    • 21.3.16. Hikma Pharmaceuticals PLC
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Key Financials
      • 21.3.16.4. SWOT Analysis
      • 21.3.16.5. Sales Footprint
      • 21.3.16.6. Strategy Overview
      • 21.3.16.7. Key Developments
        • 21.3.16.7.1. Marketing Strategies
        • 21.3.16.7.2. Channel Strategies
    • 21.3.17. Cipla Inc.
      • 21.3.17.1. Overview
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Key Financials
      • 21.3.17.4. SWOT Analysis
      • 21.3.17.5. Sales Footprint
      • 21.3.17.6. Strategy Overview
      • 21.3.17.7. Key Developments
        • 21.3.17.7.1. Marketing Strategies
        • 21.3.17.7.2. Channel Strategies
    • 21.3.18. Endo International plc
      • 21.3.18.1. Overview
      • 21.3.18.2. Product Portfolio
      • 21.3.18.3. Key Financials
      • 21.3.18.4. SWOT Analysis
      • 21.3.18.5. Sales Footprint
      • 21.3.18.6. Strategy Overview
      • 21.3.18.7. Key Developments
        • 21.3.18.7.1. Marketing Strategies
        • 21.3.18.7.2. Channel Strategies
    • 21.3.19. Otsuka Pharmaceutical Co., Ltd.
      • 21.3.19.1. Overview
      • 21.3.19.2. Product Portfolio
      • 21.3.19.3. Key Financials
      • 21.3.19.4. SWOT Analysis
      • 21.3.19.5. Sales Footprint
      • 21.3.19.6. Strategy Overview
      • 21.3.19.7. Key Developments
        • 21.3.19.7.1. Marketing Strategies
        • 21.3.19.7.2. Channel Strategies
    • 21.3.20. STI Pharma, LLC
      • 21.3.20.1. Overview
      • 21.3.20.2. Product Portfolio
      • 21.3.20.3. Key Financials
      • 21.3.20.4. SWOT Analysis
      • 21.3.20.5. Sales Footprint
      • 21.3.20.6. Strategy Overview
      • 21.3.20.7. Key Developments
        • 21.3.20.7.1. Marketing Strategies
        • 21.3.20.7.2. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology